Graves' Disease
Graves' Disease is a condition categorized within metabolic health. It is discussed separately from Graves orbitopathy, a condition context referenced in relation to mild, active, recent-onset disease.
See where Graves' Disease fits within metabolic health topics.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
May not suit people with this condition
Supplements and practices linked to problems for people with this condition.
Sea Moss (Irish Moss)supplementUnclear
Iodine supplementation can exacerbate Graves' disease and interfere with its treatment. Sea moss should be avoided in this autoimmune thyroid condition.
Open the Sea Moss (Irish Moss) page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this conditionNothing in this library is currently recorded as helping with Graves' Disease. That means nothing is on file — not that nothing exists. Only 107 of 338 catalogued supplements have a written-up profile so far.
What to avoid
Interventions recorded as making it worse1 listedHighest probability
- →SupplementsSea Moss (Irish Moss)CertaintyLowSourceReference knowledge
Iodine supplementation can exacerbate Graves' disease and interfere with its treatment. Sea moss should be avoided in this autoimmune thyroid condition.
Open Sea Moss (Irish Moss)Rationale
Sea moss provides high amounts of iodine, which can exacerbate hyperthyroidism in Graves' disease by providing substrate for uncontrolled thyroid hormone synthesis.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Graves' Disease is a condition categorized within metabolic health. It is discussed separately from Graves orbitopathy, a condition context referenced in relation to mild, active, recent-onset disease. Selenium has been described as an accepted adjunct in that specific context for populations at risk of selenium insufficiency, but not as a general substitute for antithyroid treatment. Medical conditions should be discussed with a clinician.
Evidence-backed options
Selenium has been studied as an adjunct for mild, active, recent-onset Graves orbitopathy, particularly among populations at risk of selenium insufficiency. The described course lasted six months. Its role is specific to this eye-related manifestation of Graves' disease and should not be interpreted as a general treatment for the condition.
Selenium is not presented as a substitute for antithyroid treatment. The evidence applies to a defined clinical context rather than to everyone with Graves' disease, and the available information does not establish a broader role across other disease features or patient groups. Anyone considering options for Graves' disease should discuss them with a clinician.
What to avoid
For Graves' Disease, the concern centers on added iodine. Iodine can worsen the hyperthyroidism associated with this condition and may interfere with antithyroid treatment, so iodine supplementation is flagged for avoidance.
Sea Moss (Irish Moss) is also flagged because its use is connected with iodine supplementation. In Graves' Disease, this may exacerbate the condition and interfere with treatment. The concern therefore applies to both direct iodine supplements and Sea Moss (Irish Moss) in the context of this autoimmune thyroid condition.
These cautions relate specifically to supplementation and treatment considerations; they do not establish that every source or circumstance has the same effect. Anyone with Graves' Disease can discuss supplement ingredients and treatment compatibility with a clinician, particularly when a product’s iodine content or contribution is unclear.